ReviewEuropean clinical respiratory journal2018
Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma - a systematic review and meta-analysis.
Review in European clinical respiratory journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Anti-IL-5 therapies for asthma.The Cochrane database of systematic reviews · 2022Pooled it
- The Clinical Efficacy of Type 2 Inflammation-Specific Agents Targeting Interleukins in Reducing Exacerbations in Severe Asthma: A Meta-Analysis.Yonsei medical journal · 2022Pooled it
- Adverse events of benralizumab in moderate to severe eosinophilic asthma: A meta-analysis.Medicine · 2019Pooled it
- In-Patient Pulmonary Rehabilitation to Improve Asthma Control–A Randomized Controlled Study (EPRA, Effectiveness of Pulmonary Rehabilitation for Patients with Asthma).Deutsches Arzteblatt international · 2021Trial
- Reslizumab as add-on therapy in patients with refractory asthma.BMJ open respiratory research · 2020Trial
- Efficacy and Safety of Biologic Therapies for Uncontrolled Asthma: An Overview of Systematic Reviews.Pediatric pulmonology · 2026Review
- Hyper IgE Syndromes: Understanding, Management, and Future Perspectives: A Narrative Review.Health science reports · 2025Article
- Longitudinal multi-trajectory phenotypes of severe eosinophilic asthma on type 2 biologics treatment.The World Allergy Organization journal · 2024Article
- Review
- Long-term multicenter comparison shows equivalent efficacy of monoclonal antibodies in severe asthma therapy.BMC pulmonary medicine · 2024Article
- The Evolution of Scientific Knowledge in Childhood Asthma over Time: A Surprising History.Children (Basel, Switzerland) · 2024Review
- Biologic Therapies for Asthma and Allergic Disease: Past, Present, and Future.Pharmaceuticals (Basel, Switzerland) · 2023Review
- A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database.Frontiers in pharmacology · 2023Article
- Specific Therapy for T2 Asthma.Journal of personalized medicine · 2022Review
- Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma.Journal of asthma and allergy · 2022Article
- Recent advances of eosinophils and its correlated diseases.Frontiers in public health · 2022Review
- Review
- Variability ofThe World Allergy Organization journal · 2021Article
- Indirect comparison of efficacy of dupilumabERJ open research · 2021Article
- Essential Role of Pharmacists in Asthma Care and Management.Journal of pharmacy practice · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.